Tobey J MacDonald MD
Pediatric Neuro-Oncology
Director and Aflac Chair of Pediatric Neuro-Oncology, Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta and Emory University, Professor of Pediatrics, Emory University School of Medicine
Join to View Full Profile
111 Michigan Ave NWWashington, DC 20010
Phone+1 202-884-2140
Fax+1 404-727-4455
Dr. MacDonald is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Tobey MacDonald is a pediatric hematologist/oncologist in Atlanta, GA and is affiliated with multiple hospitals in the area, including Children's Healthcare of Atlanta, Emory University Hospital, and Children's Healthcare of Atlanta. He received his medical degree from Weill Cornell Medical College of Cornell University and has been in practice 26 years. He specializes in pediatric neuro-oncology.
Education & Training
Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 1994 - 1997- Children's Hospital Los AngelesResidency, Pediatrics, 1991 - 1994
Weill Cornell MedicineClass of 1991
Cornell UniversityBA, Biology, 1983 - 1987
Certifications & Licensure
CA State Medical License 1992 - Present
GA State Medical License 2009 - 2027
DC State Medical License 1998 - 2010
VA State Medical License 1998 - 2010
MD State Medical License 1998 - 2009
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Top Doctors- Pediatric Hematology Oncology US News & World Report
Clinical Trials
- Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children Start of enrollment: 2001 Mar 01
- Cilengitide in Treating Children With Refractory Primary Brain Tumors Start of enrollment: 2003 Jul 01
- Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Start of enrollment: 2011 Sep 01
Publications & Presentations
PubMed
- ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.Theophilos Tzaridis, Jingbo Liu, Franklin Lee Chien, Anshu Malhotra, Dan Zhu
Neuro-Oncology. 2026-03-12 - Data-Driven Feedback Identifies Focused Ultrasound Exposure Regimens for Improved Nanotheranostic Targeting of the Brain.Hohyun Lee, Victor Menezes, Shiqin Zeng, Chulyong Kim, Cynthia M Baseman
Advanced Science. 2026-03-01 - 2 citationsFirst-in-child phase I trial of p-STAT3 inhibitor WP1066 in pediatric brain tumor patients.Robert C Castellino, Hope Mumme, Andrea Franson, Bing Yu, Hope Robinson
JCI Insight. 2026-02-09
Journal Articles
- White Matter Network Topology Relates to Cognitive Flexibility and Cumulative Neurological Risk in Adult Survivors of Pediatric Brain TumorsTobey MacDonald, MD, ScienceDirect
Press Mentions
Emory Cancer Researchers Can Now Track Pediatric Brain Tumors, Assess Treatment by Blood TestAugust 20th, 2025- Georgia State University Researcher Awarded $3 Million to Study Brain Cancer SurvivorsDecember 8th, 2022
- Breaching the Blood-Brain Barrier to Deliver Precious PayloadsMay 7th, 2021
Grant Support
- The Role Of Pdgfr In Medulloblastoma ProgressionNational Cancer Institute2010
- The Role Of Pdgfr In Medulloblastoma ProgressionNational Cancer Institute2006–2009
- Phase II Study Of Bevacizumab PLUS Irinotecan (CAMPTORSAR) In Children With RecrNational Center For Research Resources2007–2008
- Pbtc 007 V10b- A Phase I/II Trial Of Zd 1839 (IRESSA)National Center For Research Resources2006–2008
- Pbtc016: A Phase I, Molecular Biology And Phase II Study Of Lapatinib (Gw5720aNational Center For Research Resources2006
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
